Pure Global

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2) - Trial NCT06220604

Access comprehensive clinical trial information for NCT06220604 through Pure Global AI's free database. This Phase 3 trial is sponsored by Janssen Research & Development, LLC and is currently Recruiting. The study focuses on Plaque Psoriasis. Target enrollment is 675 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06220604
Phase 3
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06220604
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Study Focus

Plaque Psoriasis

JNJ-77242113

Interventional

drug

Sponsor & Location

Janssen Research & Development, LLC

Mitcham,Ansan-si,Anyang-si,Gwangju,Tainan, Australia,South Korea,Taiwan

Timeline & Enrollment

Phase 3

Mar 09, 2024

Sep 20, 2027

675 participants

Primary Outcome

JNJ-77242113 and Placebo Group: Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (=) 2 Grade Improvement From Baseline at Week 16,JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 16

Summary

The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with
 moderate to severe plaque psoriasis compared to placebo and deucravacitinib.

ICD-10 Classifications

Psoriasis
Large plaque parapsoriasis
Other psoriasis
Small plaque parapsoriasis
Arthropathic psoriasis

Data Source

ClinicalTrials.gov

NCT06220604

Non-Device Trial